AtaiBeckley Inc. 4

Chief Scientific Officer Glenn Frank Short had his AtaiBeckley Inc. common stock, stock options, and 150,000 RSUs canceled and cashed out at a $6.75 per share merger price plus CVRs in connection with Eli Lilly’s acquisition of the company.

On September 11, 2026, in connection with the closing of Eli Lilly and Company’s acquisition of AtaiBeckley Inc., Chief Scientific Officer Glenn Frank Short had all of his company equity awards and common stock holdings canceled and converted into cash and contingent value rights (CVRs). Each share of common stock was converted into $6.75 in cash plus one CVR worth up to an additional $2.50 contingent on future milestones. All outstanding stock options were canceled and cashed out for the intrinsic value based on the $6.75 merger price plus one CVR per underlying share, and his 150,000 restricted stock units were similarly canceled and converted into cash at $6.75 per unit plus one CVR per unit. Following these transactions, Short no longer held any AtaiBeckley equity, and the company became a wholly owned subsidiary of Eli Lilly.

Filing Facts

CIK

2081043

Ticker

ATAI

Form

4

Source Type

fda

Accession

0001140361-26-036386

Alert Tier

6